Future paths in psychopharmacology 

IF 8.3 2区医学 Q1 Medicine

Dialogues in Clinical Neuroscience Pub Date : 2019-06-01 DOI:10.31887/DCNS.2019.21.2/fthibaut

F. Thibaut

引用次数: 1

Abstract

Drug development in psychiatry is gradually moving from serendipity to personalized medicine. Some promising paths will be reviewed in this issue. 

查看原文本刊更多论文

精神药理学的未来之路

精神病学中的药物开发正逐渐从偶然发现转向个性化药物。本期将回顾一些有希望的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dialogues in Clinical Neuroscience Medicine-Psychiatry and Mental Health

CiteScore

19.30

自引率

1.20%

发文量

期刊介绍： Dialogues in Clinical Neuroscience (DCNS) endeavors to bridge the gap between clinical neuropsychiatry and the neurosciences by offering state-of-the-art information and original insights into pertinent clinical, biological, and therapeutic aspects. As an open access journal, DCNS ensures accessibility to its content for all interested parties. Each issue is curated to include expert reviews, original articles, and brief reports, carefully selected to offer a comprehensive understanding of the evolving landscape in clinical neuroscience. Join us in advancing knowledge and fostering dialogue in this dynamic field.